NeuroMab™ Anti-Tau BBB Shuttle Antibody, Clone ACI-36-3A8-Ab1
- Host Species:
- Mouse
- Species Reactivity:
- Human
- Applications:
- WB; IHC; In Vitro; In Vivo
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Storage
Research Use Only
Target
Official Name
Full Name
Alternative Names
Figure 1 shows antibody binding to phosphorylated Tau in AD and tau disease patient brain slices using the ACI-36-3A8-Ab1 antibody using TAUPIR.
Figure 2 shows the effect of anti-Tau antibody treatment after a 1-week in vivo study of the pTau epitope pT231 using MSD.
Figure 3 shows the effect of anti-Tau antibody treatment after a 1-week in vivo study of the pTau epitope pT231 using MSD.
Figure 4 shows the pTau epitope western blot after anti-Tau antibody treatment in a 1-month in vivo study.
Figure 5 shows pTau epitope western blot results after anti-Tau antibody treatment in a 3-month in vivo study.
Figure 6 shows the pTau epitope western blot after anti-Tau antibody treatment for a 3-month in vivo study using biGT biomouse.
Figure 7 shows pTau epitope Western blot results after anti-Tau antibody treatment for a 3-month in vivo study using biGT biomouse.
Figure 8 shows pTau epitope western blot results after anti-Tau antibody treatment for a 3-month in vivo study using biGT biomouse.
Figure 9 shows IHC after anti-Tau antibody treatment by ACI-36-2B6-Ab1 in a 3-month in vivo study.
Figure 10 shows IHC following anti-Tau antibody treatment with ACI-36-2B6-Ab1 in a 3-month in vivo study.
Figure 11 shows the Morris water maze results after ACI-36-2B6-Ab1 anti-Tau antibody treatment in a 3-month in vivo study.
Figure 12 shows the Morris water maze results after ACI-36-3A8-AM anti-Tau antibody treatment in a 3-month in vivo study.
Publications (0)
